RPR-200765A methanesulfonate is an orally active p38 MAPK inhibitor with an IC 50 of 0.050 μM. RPR-200765A methanesulfonate shows weak activity against Lck , and exhibits no significant activity against ERK , ZAP70 or SYK . It inhibits the production of TNFα and can be used in the research of inflammatory diseases.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TNF Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.